SCHEMBL28548632

SCHEMBL28548632

CC(=O)NNC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
MMP13 P45452 1/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP7 P09237 1/20 0.39
MMP9 P14780 1/20 0.39
KMT2A Q03164 2/20 0.39
BACE1 P56817 2/20 0.38
GPR119 Q8TDV5 2/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
MEN1 O00255 1/20 0.38
KDM4D Q6B0I6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21831019 0.86 ALDH1A1 (0.46) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL21831041 0.85 ALDH1A1 (0.44) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL21830971 0.85 MEN1 (0.46) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL28560503 0.85 DPP8 (0.40) MAPTMAPK1RAB9AKMT2AMEN1
SCHEMBL21831049 0.84 NPC1 (0.42) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL23100623 0.83 NPC1 (0.44) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL21831240 0.82 NPC1 (0.43) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL25311750 0.82 DPP8 (0.52) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL25313135 0.82 DPP8 (0.52) NPC1ALDH1A1MAPTMAPK1HTT
SCHEMBL28543172 0.82 DPP8 (0.52) NPC1ALDH1A1MAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112654621-B Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2024-05-14 CN disclosed
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 EP disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
US-20220324859-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2022-10-13 US disclosed
CN-112654621-A Substituted naphthyridinone compounds useful as T cell activators 百时美施贵宝公司 2021-04-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324859-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG NPC1 2494/4885ALDH1A1 3814/4885MAPT 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.